

March 25, 2021

To,

National Stock Exchange of India Ltd.

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East),

Mumbai - 400 051.

Fax No.: 022-26598237/38/26598347

BSE Ltd.

Market Operations Dept. P. J. Towers,

Dalal Street,

Mumbai - 400 001.

Tel: 022-22721233/4 Fax No 022-22723121

Dear Sir/ Madam,

Sub: <u>Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure</u> Requirements) Regulations, 2015.

This is to inform you that Lupin Limited has agreed in principle to subscribe to a partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid Regulations, is attached as per 'Annexure A'.

This is for your information and record.

Thanking you,

Yours faithfully,

For LUPIN LIMITED

R. V. SATAM (COMPANY SECRETARY)

ACS - 11973

Encl.: - Annexure A





## Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Clause A(1) of Part A, Schedule III of the aforesaid regulations on subscription of partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) by the Company.

a) Name of the target entity, details in brief such as size, turnover etc.:	i) Name of the Target entity: ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), hereinafter referred to as the Target entity.
	ii) Details of Target entity: The Target entity is a recently incorporated limited liability partnership ('LLP') and has not commenced any business activities.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Armslength";	No.
<ul><li>c) Industry to which the entity being acquired belongs;</li></ul>	Healthcare services.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity;	Initiative with an objective to digitize healthcare infrastructure in India towards facilitating Good Distribution Practices inter alia, in support of the National Digital Health Mission of Government of India ('Business').
<ul> <li>e) Brief details of any governmental or regulatory approvals required for the acquisition;</li> </ul>	None.
<ul> <li>f) Indicative time period for completion of the acquisition;</li> </ul>	On or before March 31, 2021.
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash infusion as capital contribution.
<ul> <li>h) Cost of acquisition or the price at which the shares are acquired;</li> </ul>	INR 40 crores.
<ul> <li>i) Percentage of shareholding/control acquired and/or number of shares acquired;</li> </ul>	Up to 20% share of profit/loss in the Target entity.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The Target entity has been incorporated on 10 <sup>th</sup> February, 2021.  The Target entity is a newly incorporated limited liability partnership ('LLP'), and has not commenced any business activities.
	The Target entity through one or more LLPs and investments/ subsidiaries would engage in the above-mentioned Business.
	There are other leading pharmaceutical companies who would be joining the LLP. The proposed structure would ensure transparent and effective competition to the benefit of patients in India.

## LUPIN LIMITED